Innovent Biologics Inc

01801: XHKG (HKG)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|LyLOCK|SxJcLOCK|ggC#Z?cq

Innovent Earnings: Provides Lofty Revenue Target for 2030; GLP-1 Revenue Robust; Fair Value Up 15%

Innovent's first-half 2026 revenue grew 45% year-on-year to CNY 8.6 billion as mazdutide, its GLP-1 drug, continues to gain market acceptance. Operating profits swung back to profitability to 12.8% from the last half of 2025.

Sponsor Center